Articles By Jack Cush, MD
Gout is Undermanaged
Gout should be one of the easiest and best managed of rheumatic disorders. However, numerous deficits exist with regard to the treatment and long-term care of gout.
Read Article
Limited Efficacy of NSAIDs in Spondyloarthritis
Prior to the biologic era, nonsteroidal antiinflammatory drugs (NSAIDs) were the mainstay of drug therapy in thos with spondyloarthritis (SpA) and ankylosing spondylitis (AS). Their role in the modern era has changed and the claims for efficacy have varied.
Read Article
Is the Jury Still Out on Triple Therapy vs. MTX + TNF inhibitor?
There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis.
Read Article
Curbside Consults - January 2017
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.
Read Article
The RheumNow Week in Review – 27 January 2017
Dr. Cush reviews highlights from the past week on RheumNow.com.
Read Article
The Challenge of Screening for Obstructive Sleep Apnea
A JAMA article presents the US Public Health Task Force review of OSA testing.
Read Article
DSB - Safety Update and Drug Shortages January 2017
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Read Article
C5a and Neutrophils as Early Mediators in Inflammatory Arthritis
Researchers from the Massachusetts General Hospital (MGH) have studied the initial steps in an animal model of inflammatory arthritis and found that complement C5a is critical to neutrophils migration into joints.
Read Article
Ties to Pharma Influences Clinical Trial Results
A study published in The BMJ shows that financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results; thereby questioning the bias in these objective trials.
Read Article
FDA Issues Draft Guidance on Biosimilar Interchangeability
Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?
Read Article
